Switching HIV meds for people on opioid therapy
Part of Mental health clinical trials.
This study sees if it's safe to switch your current HIV medication to a two-pill combo (dolutegravir and lamivudine) if you are also taking medication for opioid addiction. It aims to make treatment simpler and more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have HIV.
- Your HIV viral load has been undetectable (below 200 copies/mL) for at least 3 months.
- You are currently on stable medication for opioid addiction (like methadone or buprenorphine) and have been for at least 3 months.
- You are not infected with hepatitis B.
- Your CD4 count (immune system cells) is 200 or higher.
- You are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
This study collects data from HIV patients who start treatment with a two-drug combination of dolutegravir and lamivudine, either as their first treatment or after switching from a three-drug regimen.
This study tests whether a combination of buprenorphine (a medication for opioid addiction) and PrEP (a daily pill to prevent HIV) can help people who are leaving jail or prison stay healthy. It aims to reduce both opioid relapse and HIV risk during the transition back to the community.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.